Cargando…
Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
Osteoporosis is the most common osteolytic disease characterized by excessive osteoclast formation and resultant bone loss, which afflicts millions of patients around the world. Astilbin, a traditional herb, is known to have anti‐inflammatory, antioxidant and antihepatic properties, but its role in...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850941/ https://www.ncbi.nlm.nih.gov/pubmed/31603626 http://dx.doi.org/10.1111/jcmm.14713 |
_version_ | 1783469537827487744 |
---|---|
author | Jin, Haiming Wang, Qingqing Chen, Kai Xu, Ke Pan, Hao Chu, Feifan Ye, Zhen Wang, Ziyi Tickner, Jennifer Qiu, Heng Wang, Chao Kenny, Jacob Xu, Huazi Wang, Te Xu, Jiake |
author_facet | Jin, Haiming Wang, Qingqing Chen, Kai Xu, Ke Pan, Hao Chu, Feifan Ye, Zhen Wang, Ziyi Tickner, Jennifer Qiu, Heng Wang, Chao Kenny, Jacob Xu, Huazi Wang, Te Xu, Jiake |
author_sort | Jin, Haiming |
collection | PubMed |
description | Osteoporosis is the most common osteolytic disease characterized by excessive osteoclast formation and resultant bone loss, which afflicts millions of patients around the world. Astilbin, a traditional herb, is known to have anti‐inflammatory, antioxidant and antihepatic properties, but its role in osteoporosis treatment has not yet been confirmed. In our study, astilbin was found to have an inhibitory effect on the RANKL‐induced formation and function of OCs in a dose‐dependent manner without cytotoxicity. These effects were attributed to its ability to suppress the activity of two transcription factors (NFATc1 and c‐Fos) indispensable for osteoclast formation, followed by inhibition of the expression of bone resorption‐related genes and proteins (Acp5/TRAcP, CTSK, V‐ATPase‐d2 and integrin β3). Furthermore, we examined the underlying mechanisms and found that astilbin repressed osteoclastogenesis by blocking Ca(2+) oscillations and the NF‐κB and MAPK pathways. In addition, the therapeutic effect of MA on preventing bone loss in vivo was further confirmed in an ovariectomized mouse model. Therefore, considering its ability to inhibit RANKL‐mediated osteoclastogenesis and the underlying mechanisms, astilbin might be a potential candidate for treating osteolytic bone diseases. |
format | Online Article Text |
id | pubmed-6850941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68509412019-12-01 Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis Jin, Haiming Wang, Qingqing Chen, Kai Xu, Ke Pan, Hao Chu, Feifan Ye, Zhen Wang, Ziyi Tickner, Jennifer Qiu, Heng Wang, Chao Kenny, Jacob Xu, Huazi Wang, Te Xu, Jiake J Cell Mol Med Original Articles Osteoporosis is the most common osteolytic disease characterized by excessive osteoclast formation and resultant bone loss, which afflicts millions of patients around the world. Astilbin, a traditional herb, is known to have anti‐inflammatory, antioxidant and antihepatic properties, but its role in osteoporosis treatment has not yet been confirmed. In our study, astilbin was found to have an inhibitory effect on the RANKL‐induced formation and function of OCs in a dose‐dependent manner without cytotoxicity. These effects were attributed to its ability to suppress the activity of two transcription factors (NFATc1 and c‐Fos) indispensable for osteoclast formation, followed by inhibition of the expression of bone resorption‐related genes and proteins (Acp5/TRAcP, CTSK, V‐ATPase‐d2 and integrin β3). Furthermore, we examined the underlying mechanisms and found that astilbin repressed osteoclastogenesis by blocking Ca(2+) oscillations and the NF‐κB and MAPK pathways. In addition, the therapeutic effect of MA on preventing bone loss in vivo was further confirmed in an ovariectomized mouse model. Therefore, considering its ability to inhibit RANKL‐mediated osteoclastogenesis and the underlying mechanisms, astilbin might be a potential candidate for treating osteolytic bone diseases. John Wiley and Sons Inc. 2019-10-11 2019-12 /pmc/articles/PMC6850941/ /pubmed/31603626 http://dx.doi.org/10.1111/jcmm.14713 Text en © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Jin, Haiming Wang, Qingqing Chen, Kai Xu, Ke Pan, Hao Chu, Feifan Ye, Zhen Wang, Ziyi Tickner, Jennifer Qiu, Heng Wang, Chao Kenny, Jacob Xu, Huazi Wang, Te Xu, Jiake Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis |
title | Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis |
title_full | Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis |
title_fullStr | Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis |
title_full_unstemmed | Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis |
title_short | Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis |
title_sort | astilbin prevents bone loss in ovariectomized mice through the inhibition of rankl‐induced osteoclastogenesis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850941/ https://www.ncbi.nlm.nih.gov/pubmed/31603626 http://dx.doi.org/10.1111/jcmm.14713 |
work_keys_str_mv | AT jinhaiming astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT wangqingqing astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT chenkai astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT xuke astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT panhao astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT chufeifan astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT yezhen astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT wangziyi astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT ticknerjennifer astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT qiuheng astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT wangchao astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT kennyjacob astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT xuhuazi astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT wangte astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis AT xujiake astilbinpreventsbonelossinovariectomizedmicethroughtheinhibitionofranklinducedosteoclastogenesis |